Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

ABIRATERONA OLPHA 250 MG COMPRIMIDOS EFG - CIMA-AEMPS Drug Approval Details

Approvals/CIMA-AEMPS/ABIRATERONA OLPHA 250 MG COMPRIMIDOS EFG

Approved

STANDARD

ABIRATERONA OLPHA 250 MG COMPRIMIDOS EFG

Olpha As🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: Dec 18, 2023
Approval ID: f8981aa8c0fba43a
Company: Olpha As
Type: Standard

Approval Details

Approval Id: f8981aa8c0fba43a
Drug Cima Aemps Name: ABIRATERONA OLPHA 250 MG COMPRIMIDOS EFG
Register Number: 89200
Holder Company Name: Olpha As
Marketing Company Name: Olpha As
Authorization Date: 2023-12-18
Dosage Form: COMPRIMIDO
Dose: 250 mg
Route Of Administration: VÍA ORAL
Prescription Type: Diagnóstico Hospitalario
Commercialized: No
Company Name: Olpha As

Active Ingredients

ABIRATERONA ACETATO

250 mg

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

Dec 18, 2023

Approval ID

f8981aa8c0fba43a

Type

Standard

Back to CIMA-AEMPS Approvals